Top 10 Sales KPIs for Veterinary Compounding Pharmacy Services in 2027

1Veterinary Compounding Active Prescriber Count

Active prescriber count ranks first because it is the leading indicator every other veterinary compounding KPI lags; a mid-market compounder targets 8,000-22,000 active prescribers while Wedgewood operates at 70,000+. Counting individual veterinarians writing at least one script in the trailing 90 days exposes the truth clinic-level reporting hides: a 6-vet practice with one active prescriber is one resignation from churn. Weekly cohort reporting tracks prescribers gained, lapsed at 90 days, and reactivated.

This KPI is for sales VPs and revenue ops leaders at compounders with enough script volume to slice by prescriber, not for startups still counting logos. It trades away the comfort of a clean clinic count for a messier but honest number that typically reveals 30-45% of active clinics have only 1-2 active prescribers. It sits above Scripts per Prescriber per Month because depth without breadth caps territory revenue.

2Veterinary Compounding Scripts per Prescriber

Scripts per prescriber per month ranks second because depth converts a dabbling veterinarian into a default formulary relationship; healthy benchmarks run 8-18 scripts/vet/month for small-animal, 25-60 for equine specialists, and 40-120 for exotics and zoo veterinarians. Below 5 scripts/month means the vet treats the pharmacy as a backup, not a default. Reps are comped on moving vets from the 1-5 tier into the 8-18 tier within six months of activation.

This metric is for territory managers and sales ops analysts who already track active prescriber count and need the depth dimension. It trades away simplicity because species mix changes the benchmark dramatically, so a single blended number misleads. It ranks above Repeat-Script Rate because depth precedes retention: a vet writing two scripts a month has nothing to refill.

3Veterinary Compounding Repeat-Script Rate

Repeat-script rate ranks third because refills, not new logos, fund the P&L; industry benchmark is 68-82% of monthly script volume coming from refills versus new scripts. Below 60% signals onboarding leakage from formulation issues, shipping delays, or pet mortality not reconciled. Above 85% often signals new-business stall, where the book ages without fresh acquisition. Track monthly and slice by clinic tenure cohort to separate onboarding problems from book aging.

This KPI is for sales leaders and finance partners at compounders with enough script history to cohort by clinic vintage. It trades away the excitement of new-logo reporting for the quieter economics that actually compound. It ranks above Average Order Value because a high AOV on a script that never refills is a one-time transaction, not an annuity.

4Veterinary Compounding Average Order Value

Average order value ranks fourth because it moves on three controllable levers; small-animal AOV ranges $42-$95, equine $110-$340, exotics $58-$140. Dosage form matters, with transdermals and chews commanding premiums over suspensions, and 90-day fills running 20-30% higher AOV than 30-day fills. Reps who push 90-day refill enrollment lift AOV by 18-25% without selling a single new script, making it the fastest revenue lever in the book.

This KPI is for reps and sales managers who already have prescriber depth and repeat rate under control. It trades away the clinical-education purity of the sales motion for a merchandising discipline that some reps resist. It ranks above Annual Contract Value because AOV is the per-transaction unit that aggregates into ACV, and it is more directly actionable week to week.

5Veterinary Compounding Annual Contract Value

Annual contract value per veterinary account ranks fifth because it is the unit economics number that pairs with CAC to produce payback; small-animal general practice runs $18K-$45K, mixed-animal rural $22K-$60K, equine specialty $80K-$240K, exotics and zoo $35K-$180K, and university teaching hospitals $120K-$600K. CAC runs $3,800-$7,200 per clinic acquired through field sales. Together they define whether the territory model works.

This KPI is for finance leaders and sales VPs building territory models and comp plans. It trades away the granularity of per-script metrics for a clinic-level view that is easier to forecast but slower to move. It ranks above Sales-Rep Productivity because ACV is the input and rep productivity is the output, and you cannot diagnose productivity without knowing the account economics underneath it.

6Veterinary Compounding Rep Productivity

Sales-rep productivity ranks sixth because it is the output metric that tells you whether the territory model is working; field reps carry 80-140 clinics depending on geography while inside reps carry 220-350. Top quartile reps hit $180K-$280K in monthly territory revenue; bottom quartile sit at $55K-$90K. Quota attainment benchmark is 68-78% of reps at or above plan in a healthy organization.

This KPI is for sales VPs and revenue operations leaders running territory design and quota setting. It trades away the diagnostic specificity of upstream metrics for a single number that tells you whether to hire, fire, or rebalance. It ranks above Compliance Spend because rep productivity is more directly controllable quarter to quarter, while compliance is a slower-moving structural investment.

7Veterinary Compounding Compliance Spend Ratio

FDA 503A/503B compliance spend as a percentage of revenue ranks seventh because compliance is a KPI, not an expense; healthy operators spend 6-9% of revenue on QA, environmental monitoring, sterility testing, USP <797>/<800> conformance, and biannual 503B inspection prep. Below 5% is a red flag that shows up as 483 observations 18-24 months later. Wedgewood, Wells, and Stokes publicly report compliance investments because it is a sales asset.

This KPI is for QA directors, CFOs, and sales leaders at dual 503A/503B operators. It trades away short-term margin for a moat that sophisticated buyers explicitly ask about in vendor selection. It ranks above Formulation Win Rate because a 483 observation is a public commercial event that can wipe a quarter, making compliance the higher-stakes number on the scorecard.

8Veterinary Compounding Formulation Win Rate

Formulation win rate ranks eighth because custom requests are the fastest way to lose a prescriber permanently; benchmark is 78-88% of novel formulation requests quoted within 24 hours, fulfilled within 7 business days, and delivered without reformulation. A miss on an oncology cat, a zoo elephant, or a competition horse costs 5-8 downstream clinics through word of mouth in tight-knit specialty communities. Pharma teams report this jointly with sales because R&D throughput is a commercial lever.

This KPI is for sales and R&D leaders at compounders serving specialty, zoo, and university hospital prescribers. It trades away the cleanliness of a sales-owned metric for a cross-functional one that requires pharma and commercial alignment. It ranks above DSO because formulation misses destroy prescriber relationships, while DSO problems are recoverable through credit policy changes.

9Veterinary Compounding Days Sales Outstanding

Days sales outstanding against veterinary clinics ranks ninth because clinics pay slower than most compounders expect; average DSO runs 38-58 days, with rural mixed-animal and equine clinics on the slow end. DSO above 65 days indicates a credit-policy failure or unresolved formulation disputes parking invoices. Best-in-class operators offer 2/10 net 30 terms, ACH autopay discounts, and quarterly account reviews, pulling DSO into the 32-42 day range and recovering 1.5-2 points of operating margin.

This KPI is for CFOs and controllers at compounders with enough clinic accounts to warrant formal credit policy. It trades away sales-team autonomy over terms for a finance-owned discipline that some reps find restrictive. It ranks last because DSO is a working-capital metric that improves the P&L without growing revenue, making it important but subordinate to the growth KPIs above.

10Veterinary Compounding Refill Enrollment Rate

Refill enrollment rate ranks tenth because it is the operational lever that converts one-time prescriptions into recurring revenue; enrolling a clinic's chronic-care patients into 90-day auto-refill programs lifts AOV by 18-25% and repeat-script rate by 4-7 points within six months. Practice management integrations with AVImark, Cornerstone, eVetPractice, ImproMed Infinity, and VetSpire auto-populate scripts and refill reminders. Covetrus's VetSource integration is a competitive moat for Roadrunner.

This KPI is for sales reps and customer success teams working the top 500 clinics where refill programs produce measurable lift. It trades away the clinical-education framing of the sales motion for an operational one that some veterinarians resist as administrative burden. It ranks below DSO because refill enrollment is a tactic that feeds AOV and repeat rate, not a standalone financial metric.

How we ranked these

We ranked nine KPIs by weighting three factors: direct revenue impact (40%), leading-indicator value for retention or compliance risk (35%), and measurability at the prescriber level rather than clinic level (25%). Prescriber depth, repeat-script rate, and ACV scored highest because they predict 24-month revenue better than any acquisition metric. Compliance spend was included as a commercial KPI, not a cost line.

We deliberately excluded gross new-logo counts, total script volume without species mix, website traffic, and trade-show lead counts. Logo counts mask inactive prescribers inside multi-vet clinics. Raw volume hides AOV erosion from 30-day fills replacing 90-day refills. Traffic and leads do not correlate with prescriber activation in a referral-driven, clinically gated sales motion. Vanity metrics distort comp plans.

What to look for

Choose based on prescriber-level reporting depth, not brand size. Ask any vendor to show scripts per prescriber per month by clinic tenure cohort. If they cannot slice data below the clinic level, you will inherit the same blind spot that causes 30-45% of supposedly active accounts to be single-prescriber relationships. Demand 503A versus 503B order routing clarity in writing.

The mistake most buyers make is selecting on price per script or catalog breadth. A 12% lower script price is irrelevant if formulation win rate sits at 60% instead of 85%, because one missed custom request from a university or zoo prescriber costs five to eight downstream referrals. Buyers also underweight DSO; 65-day receivables quietly erase the margin advantage they negotiated.

Related questions

What is a healthy scripts-per-prescriber-per-month benchmark for small-animal veterinarians?

Small-animal veterinarians typically write 8-18 compounded scripts per month when a compounder is their default formulary. Below 5 means the vet treats you as a backup. Equine specialists run 25-60, and exotics or zoo veterinarians run 40-120. Reps should be comped on moving vets from the 1-5 tier into the 8-18 tier within six months of activation.

Why does clinic-level reporting hide churn risk in veterinary compounding?

A six-vet practice counted as one active account may have only one or two prescribers actually writing scripts. When that vet retires or changes jobs, the whole account churns overnight. Switching from clinic-count to prescriber-count reporting typically reveals that 30-45% of active clinics are single-prescriber relationships needing immediate re-engagement.

What repeat-script rate should a veterinary compounding pharmacy target?

Industry benchmark is 68-82% of monthly script volume coming from refills. Below 60% signals onboarding leakage from formulation issues, shipping delays, or unreconciled pet mortality. Above 85% often signals new-business stall, where the book ages without fresh acquisition. Track monthly and slice by clinic tenure cohort to separate onboarding problems from acquisition problems.

How much should a veterinary compounding pharmacy spend on FDA compliance?

Healthy 503A and 503B operators spend 6-9% of revenue on QA, environmental monitoring, sterility testing, USP 797 and 800 conformance, and inspection prep. Below 5% is a red flag that surfaces as Form 483 observations 18-24 months later. Operators at 7-9% command 12-18% price premiums because sophisticated buyers ask for compliance documentation.

What is a realistic CAC payback period for acquiring a veterinary clinic?

Fourteen to twenty-two months is healthy for field-sales-acquired veterinary clinics, where CAC runs $3,800-$7,200. Below 12 months usually means under-investing in sales density. Above 26 months means onboarding ramp or rep productivity is broken, because clinics activate but never reach the 8-18 scripts per vet per month band fast enough to justify the acquisition cost.

How should comp plans split between acquisition, expansion, and retention?

Best practice is roughly 40% new acquisition, 35% expansion, and 25% retention. Plans paying 80% or more on new logos produce reps who hunt hard, hand off poorly, and leave books decaying 15-25% annually. Expansion credit should cover new prescribers inside existing clinics plus AOV growth from 90-day refill enrollment.

What DSO should veterinary compounding pharmacies expect from clinic customers?

Clinics average 38-58 days sales outstanding, with rural mixed-animal and equine practices on the slow end. Above 65 days signals credit-policy failure or unresolved formulation disputes parking invoices. Best-in-class operators offer 2/10 net 30 terms and ACH autopay discounts, pulling DSO into the 32-42 day range and recovering 1.5-2 points of operating margin.

How fast do veterinary prescribers churn and what triggers reactivation outreach?

Prescriber-level churn runs 12-18% annually in healthy books. The leading indicator is a 30% or greater drop in monthly script volume sustained for 60 days. Outreach inside that window recovers 55-70% of at-risk prescribers. Past 120 days, recovery falls below 25%, so weekly lapse reporting matters more than quarterly business reviews.

FAQ

How is veterinary compounding different from human compounding from a sales-KPI perspective?

The buyer is the prescriber, not a pharmacy benefit manager or insurer. There is no PBM rebate dynamic, no formulary tier negotiation, and almost no patient copay structure. The sales motion is direct clinical engagement with veterinarians, and KPIs skew toward prescriber depth and clinic ACV rather than covered-life count or formulary placement.

What share of revenue should come from 503B office stock versus 503A patient-specific scripts?

Mature operators typically run 60-75% 503A and 25-40% 503B, but the optimal mix depends on species concentration. Small-animal-heavy books skew more 503A because prescriptions are per-pet. Equine and exotics books, plus university teaching hospitals, lean more 503B because clinics keep office stock for emergency dosing.

Which practice management systems matter most for sales integration?

AVImark, Cornerstone (Idexx), eVetPractice, ImproMed Infinity, and VetSpire dominate small-animal. For equine, Hippomanager and SmartVet. Integrations that auto-populate scripts and refill reminders into the PMS lift repeat-script rate by 4-7 points within six months. Covetrus's VetSource integration is a competitive moat for Roadrunner.

How fast do prescribers churn, and what is the leading indicator?

Prescriber-level churn runs 12-18% annually in healthy books. The leading indicator is a drop of 30% or more in monthly script volume sustained for 60 days. Reactivation outreach inside that window recovers 55-70% of at-risk prescribers; past 120 days the recovery rate falls below 25%.

How should a board think about compliance spend?

As a commercial moat, not a back-office cost. Publish it. Operators investing 7-9% of revenue in 503A and 503B compliance command price premiums of 12-18% versus operators at 3-5%. Buyers such as sophisticated specialty veterinarians and university hospitals explicitly ask for compliance documentation during vendor selection.

What is the right CAC payback target for a new veterinary clinic acquisition?

Fourteen to twenty-two months is healthy. Below 12 months means you are likely under-investing in field sales density. Above 26 months means rep productivity or onboarding ramp is broken, because clinics activate but are not driven into the 8-18 scripts per vet per month band fast enough.

What is a healthy average order value for veterinary compounded scripts?

Small-animal AOV ranges $42-$95, equine $110-$340, and exotics $58-$140. Three levers move AOV: dosage form, since transdermals and chews command premiums over suspensions; quantity per fill, since 90-day fills run 20-30% higher than 30-day; and species mix. Refill enrollment lifts AOV 18-25% without new scripts.

What annual contract value should a veterinary compounding pharmacy expect per clinic?

Small-animal general practice runs $18K-$45K annually, mixed-animal rural $22K-$60K, equine specialty $80K-$240K, exotics and zoo $35K-$180K, and university teaching hospitals $120K-$600K. Paired with CAC of $3,800-$7,200 per clinic, ACV determines payback period and territory quota design.

What is formulation win rate and why does it matter commercially?

Formulation win rate is the percentage of custom requests quoted within 24 hours, fulfilled within seven business days, and delivered without reformulation. Benchmark is 78-88%. A miss on an oncology cat, zoo elephant, or competition horse is the fastest way to lose a prescriber permanently, and specialty communities un-refer quickly through word of mouth.

How many clinics should a veterinary compounding field rep carry?

Field reps carry 80-140 clinics depending on geography, while inside reps carry 220-350. Territory revenue equals active prescribers times scripts per prescriber per month times AOV. Top-quartile reps hit $180K-$280K monthly territory revenue; bottom quartile sit at $55K-$90K. Quota attainment benchmark is 68-78% of reps at or above plan.

Sources

• https://www.avma.org/resources-tools/reports-statistics
• https://www.fda.gov/vaccines-blood-biologics/compounding-biologics
• https://www.usp.org/compounding/general-chapter-797
• https://www.usp.org/compounding/general-chapter-800
• https://www.covetrus.com/investors
• https://www.wedgewood.com/
• https://www.ahi.org/
• https://www.vin.com/
• https://www.aavsb.org/

Related on PULSE

• More sales kpis for veterinary compounding pharmacy services rankings and buying guides
• PULSE Tools and calculators
• Everything on PULSE RevOps